Interestingly, the high activity observed for these signatures can explain the sensitivity of some of the KRAS WT (nonamplified) cell lines among the top 20 sensitive cell lines (Fig. 1B; Supplementary Table S2), including the MKN45 cell line which carries an MET amplification, suggesting a wider therapeutic use of the pan-KRAS inhibitors in cancers beyond those with KRAS WT amplifications and mutations. Here, KRAS is linked to cancer.